UNASSIGNED: The main first-line treatment strategy for @entity726 is to reduce intraocular pressure (IOP) by @entity551 medications, but many @entity1 require multiple medications for adequate IOP control. Fixed-combination therapies provide several benefits, including simplified treatment regimens, theoretical improved treatment adherence, elimination of the potential for washout of the first drug by the second, and the reduction in ocular exposure to preservatives. b-Adrenoceptor antagonists (particularly 0.5% @entity6839 ) are the most commonly used agents in combination with other classes of drugs as fixed-combination eyedrops, but they are contraindicated in many @entity1 , owing to local @entity566 or systemic side effects. A fixed-combination preparation without a b-blocker is therefore warranted. This paper reviews the clinical effectiveness of @entity15572 1% and @entity16495 0.2% fixed combination (BBFC) for use in @entity1 with primary @entity1538 and @entity2790 . We searched PubMed and the ClinicalTrials.gov registry, and identified three randomized controlled trials comparing BBFC vs its constituents ( @entity16495 vs @entity15572 ), and one comparing BBFC with unfixed @entity16495 and @entity15572 . All of the studies demonstrated mean diurnal IOP to be statistically significantly lower in the BBFC group compared with constituent groups and noninferior to that with the concomitant group using two separate bottles. The safety profile of BBFC was consistent with that of its individual components, the most common ocular adverse events being @entity2194 , @entity227 , and @entity56 . Common systemic adverse effects included @entity2342 , oral dryness, @entity1295 , somnolence, and decreased alertness. BBFC seems to be a promising new fixed combination for use in @entity726 @entity1 . However, long-term effects of BBFC on IOP, treatment adherence, and safety need to be determined.

Clinical effectiveness of @entity15572 1%- @entity16495 0.2% fixed combination for primary XXXX and @entity2790 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity15572 :: ('MESH:C111827', 'Chemical') :: ['brinzolamide'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular hyperemia'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual disturbances'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma'] @entity6839 :: ('MESH:D013999', 'Chemical') :: ['timolol'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity16495 :: ('MESH:C015620', 'Chemical') :: ['brimonidine'] @entity2790 :: ('MESH:D009798', 'Disease') :: ['ocular hypertension'] @entity56 :: ('MESH:D004342', 'Disease') :: ['ocular allergic reactions'] @entity551 :: ('MESH:D007022', 'Disease') :: ['topical ocular hypotensive'] @entity2342 :: ('MESH:D004408', 'Disease') :: ['altered taste sensation']
@entity1538 :: (MESH:D005902,Disease) :: ['open-angle glaucoma']
